{
  "content": "Diagnosis:\nLocally advanced pancreatic acinar cell carcinoma with liver metastases\n\nStaging:\nT4N0M1, diagnosed March 2024\nMSI-high, TMB 35 mut/Mb\n\nTreatment History:\nCycle 1-2 FOLFIRINOX March-April 2024\nTransitioned to pembrolizumab monotherapy May 2024 due to Grade 3 peripheral neuropathy\n\nCurrent Status:\nPartial response to immunotherapy\nCT 15 June 2024 shows 30% reduction in pancreatic mass (6.8cm to 4.7cm) and 40% reduction in liver metastases\n\nCurrent Symptoms:\nFatigue improved (grade 1)\nAppetite returning with 2kg weight gain\nNeuropathy improving (grade 1)\nNew grade 2 pruritic rash\n\nExamination:\nPS 1\nVitals stable\nRash affecting trunk and limbs (~20% BSA)\nAbdomen soft, mild epigastric tenderness\n\nBlood Results:\nLFTs improving - ALT 45 (prev 120), ALP 150 (prev 280)\nCA19-9 trending down from 1200 to 450\n\nAssessment and Plan:\nGood partial response to pembrolizumab with improving symptoms. Managing immune-related rash with topical steroids. Continue pembrolizumab with next cycle due 28 June. Arrange CT reassessment after cycle 4. Review in 3 weeks with blood tests.",
  "output": {
    "primary_cancer": {
      "site": "pancreas body",
      "year": 2024,
      "month": 3,
      "metastases": "liver metastases",
      "tnm_stage": "T4N0M1",
      "histopathology_status": "acinar cell carcinoma",
      "biomarker_status": "MSI-high, TMB 35 mut/Mb",
      "cancer_timeline": [
        {
          "type": "treatment_systemic_start",
          "value": "Started FOLFIRINOX chemotherapy",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_change",
          "value": "Switched from FOLFIRINOX to pembrolizumab monotherapy due to Grade 3 peripheral neuropathy",
          "year": 2024,
          "month": 5
        },
        {
          "type": "anatomical_finding",
          "value": "CT shows 30% reduction in pancreatic mass (6.8cm to 4.7cm) and 40% reduction in liver metastases",
          "year": 2024,
          "month": 6
        },
        {
          "type": "laboratory_finding",
          "value": "CA19-9 decreased from 1200 to 450",
          "year": 2024,
          "month": 6
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "PS 1"
      },
      {
        "type": "current_symptom",
        "value": "Grade 1 fatigue"
      },
      {
        "type": "current_symptom",
        "value": "Grade 2 pruritic rash affecting trunk and limbs (~20% BSA)"
      },
      {
        "type": "current_symptom",
        "value": "Grade 1 peripheral neuropathy"
      },
      {
        "type": "examination_finding",
        "value": "Mild epigastric tenderness"
      },
      {
        "type": "investigation_finding",
        "value": "Improving LFTs - ALT 45 (previously 120), ALP 150 (previously 280)"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Metastatic pancreatic acinar cell carcinoma showing good partial response to pembrolizumab after switching from FOLFIRINOX due to toxicity"
      },
      {
        "type": "latest_treatment_response",
        "value": "Partial response with 30% reduction in pancreatic mass and 40% reduction in liver metastases"
      },
      {
        "type": "latest_treatment_toxicity",
        "value": "Grade 2 immune-related rash requiring topical steroids"
      },
      {
        "type": "update_to_treatment",
        "value": "Continuing pembrolizumab with next cycle due 28 June"
      },
      {
        "type": "planned_investigation",
        "value": "CT reassessment after cycle 4"
      },
      {
        "type": "follow_up_referral",
        "value": "Review in 3 weeks with blood tests"
      }
    ]
  }
}